Literature DB >> 19523825

A stabilized demethoxyviridin derivative inhibits PI3 kinase.

Hushan Yuan1, Monica T Pupo, Joe Blois, Adam Smith, Ralph Weissleder, Jon Clardy, Lee Josephson.   

Abstract

The viridins like demethoxyviridin (Dmv) and wortmannin (Wm) are nanomolar inhibitors of the PI3 kinases, a family of enzymes that play key roles in a host of regulatory processes. Central to the use of these compounds to investigate the role of PI3 kinase in biological systems, or as scaffolds for drug development, are the interrelated issues of stability, chemical reactivity, and bioactivity as inhibitors of PI3 kinase. We found that Dmv was an even more potent inhibitor of PI3 kinase than Wm. However, Dmv was notably less stable than Wm in PBS, with a half-life of 26min versus Wm's half-life of 3470min. Dmv, like Wm, disappeared in culture media with a half-life of less than 1min. To overcome Dmv's instability, it was esterified at the C1 position, and then reacted with glycine at the C20 position. The resulting Dmv derivative, termed SA-DmvC20-Gly had a half-life of 218min in PBS and 64min in culture media. SA-DmvC20-Gly underwent an exchange reaction at the C20 position with N-acetyl lysine in a manner similar to a WmC20 derivative, WmC20-Proline. SA-DmvC20-Gly inhibited PI3 kinase with an IC(50) of 44nM, compared to Wm's IC(50) of 12nM. These results indicate that the stability of Dmv can be manipulated by reactions at the C1 and C20 positions, while substantially maintaining its ability to inhibit PI3 kinase. Our results indicate it may be possible to obtain stabilized Dmv derivatives for use as PI3 kinase inhibitors in biological systems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523825      PMCID: PMC2877487          DOI: 10.1016/j.bmcl.2009.05.105

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase.

Authors:  L C Creemer; H A Kirst; C J Vlahos; R M Schultz
Journal:  J Med Chem       Date:  1996-12-06       Impact factor: 7.446

2.  Covalent reactions of wortmannin under physiological conditions.

Authors:  Hushan Yuan; Katie R Barnes; Ralph Weissleder; Lewis Cantley; Lee Josephson
Journal:  Chem Biol       Date:  2007-03

3.  Wortmannin-C20 conjugates generate wortmannin.

Authors:  Hushan Yuan; Ji Luo; Ralph Weissleder; Lewis Cantley; Lee Josephson
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

4.  Chemistry and biology of wortmannin.

Authors:  Peter Wipf; Robert J Halter
Journal:  Org Biomol Chem       Date:  2005-04-20       Impact factor: 3.876

5.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Authors:  Nathan T Ihle; Ryan Williams; Sherry Chow; Wade Chew; Margareta I Berggren; Gillian Paine-Murrieta; Daniel J Minion; Robert J Halter; Peter Wipf; Robert Abraham; Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2004-07       Impact factor: 6.261

6.  Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.

Authors:  Peter Wipf; Daniel J Minion; Robert J Halter; Margareta I Berggren; Caroline B Ho; Gary G Chiang; Lynn Kirkpatrick; Robert Abraham; Garth Powis
Journal:  Org Biomol Chem       Date:  2004-06-14       Impact factor: 3.876

7.  Abrogation of antibody-induced arthritis in mice by a self-activating viridin prodrug and association with impaired neutrophil and endothelial cell function.

Authors:  Lars Stangenberg; Chris Ellson; Virna Cortez-Retamozo; Adriana Ortiz-Lopez; Hushan Yuan; Joseph Blois; Ralph A Smith; Michael B Yaffe; Ralph Weissleder; Christophe Benoist; Diane Mathis; Lee Josephson; Umar Mahmood
Journal:  Arthritis Rheum       Date:  2009-08

8.  Slow self-activation enhances the potency of viridin prodrugs.

Authors:  Joseph Blois; Hushan Yuan; Adam Smith; Michael E Pacold; Ralph Weissleder; Lewis C Cantley; Lee Josephson
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

9.  Synthesis of fluorescent derivatives of wortmannin and demethoxyviridin as probes for phosphatidylinositol 3-kinase.

Authors:  José-Luis Giner; Karen A Kehbein; James A Cook; Michele C Smith; Chris J Vlahos; John A Badwey
Journal:  Bioorg Med Chem Lett       Date:  2006-02-07       Impact factor: 2.823

10.  Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media.

Authors:  Julianne L Holleran; Merrill J Egorin; Eleanor G Zuhowski; Robert A Parise; Steven M Musser; Su-shu Pan
Journal:  Anal Biochem       Date:  2003-12-01       Impact factor: 3.365

View more
  4 in total

Review 1.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  The early stage formation of PI3K-AMPAR GluR2 subunit complex facilitates the long term neuroprotection induced by propofol post-conditioning in rats.

Authors:  Haiyun Wang; Guolin Wang; Chenxu Wang; Ying Wei; Zhiting Wen; Chunyan Wang; Ai Zhu
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

3.  An in vitro model of antibody-enhanced killing of the intracellular parasite Leishmania amazonensis.

Authors:  Katherine N Gibson-Corley; Marie M Bockenstedt; Huijuan Li; Paola M Boggiatto; Yashdeep Phanse; Christine A Petersen; Bryan H Bellaire; Douglas E Jones
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

4.  Biosynthetic pathway for furanosteroid demethoxyviridin and identification of an unusual pregnane side-chain cleavage.

Authors:  Gao-Qian Wang; Guo-Dong Chen; Sheng-Ying Qin; Dan Hu; Takayoshi Awakawa; Shao-Yang Li; Jian-Ming Lv; Chuan-Xi Wang; Xin-Sheng Yao; Ikuro Abe; Hao Gao
Journal:  Nat Commun       Date:  2018-05-09       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.